SGHT
Sight Sciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$8.30
−1.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 83.4M | 77.4M | 79.9M | 81.1M | 71.3M |
| Cost of Revenue | 10.0M | 10.7M | 11.6M | 11.9M | 12.4M |
| Gross Profit | 73.3M | 66.7M | 68.3M | 69.2M | 59.0M |
| Operating Expenses | |||||
| R&D Expense | 10.8M | 14.6M | 18.0M | 17.6M | 22.9M |
| SG&A Expense | 90.4M | 89.2M | 100.8M | 108.9M | 120.1M |
| General & Admin Expense | 22.8M | — | 99.4M | 106.8M | 117.5M |
| Selling & Marketing Expense | — | — | 1.4M | 2.1M | 2.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 101.2M | 103.8M | 118.8M | 126.4M | 142.9M |
| Cost and Expenses | 111.3M | 114.5M | 130.4M | 138.3M | 155.3M |
| Operating Income (EBIT) | (27.9M) | (37.1M) | (50.5M) | (57.3M) | (84.0M) |
| Non-Operating | |||||
| Interest Income | 834.0K | 4.0M | — | — | — |
| Interest Expense | 2.6M | 5.1M | 4.7M | 5.4M | 4.5M |
| Net Interest Income | (1.8M) | (1.2M) | (4.7M) | (5.4M) | (4.5M) |
| Other Non-Op Income/Expense | (1.9M) | (1.3M) | (739.0K) | 1.8M | (2.2M) |
| Non-Operating Income (excl Interest) | (1.7M) | (3.8M) | (3.9M) | (7.2M) | (2.2M) |
| EBT (Pre-Tax Income) | (29.8M) | (38.4M) | (51.3M) | (55.4M) | (86.2M) |
| Income Tax Expense | (32.0K) | 10.0K | 236.0K | 110.0K | 47.0K |
| Bottom Line | |||||
| Net Income | (29.8M) | (38.4M) | (51.5M) | (55.5M) | (86.2M) |
| Earnings from Cont. Ops | (29.8M) | (38.4M) | (51.5M) | (55.5M) | (86.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (29.8M) | (38.4M) | (51.5M) | (55.5M) | (86.2M) |
| Per Share | |||||
| Basic EPS | ($0.56) | ($0.74) | ($1.03) | ($1.14) | ($1.80) |
| Diluted EPS | ($0.56) | ($0.74) | ($1.03) | ($1.14) | ($1.80) |
| Revenue Per Share | $1.53 | $1.48 | $1.59 | $1.67 | $1.49 |
| Shares | |||||
| Basic Shares Outstanding | 54.5M | 52.1M | 50.1M | 48.6M | 47.8M |
| Diluted Shares Outstanding | 54.5M | 52.1M | 50.1M | 48.6M | 47.8M |
| Profitability Metrics | |||||
| EBITDA | (25.7M) | (32.8M) | (45.9M) | (49.4M) | (80.5M) |
| D&A | 410.0K | 487.0K | 712.0K | 614.0K | 1.3M |
| EBIT | (26.2M) | (33.3M) | (46.6M) | (50.0M) | (81.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026